Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label study to assess systemic plasma levels of calcitriol,
calcium homeostasis and safety in adults with plaque-type psoriasis under conditions of
maximized use of CD 2027 3µg/g oily spray twice daily (6 g daily), applied to 20% of BSA for
3 weeks.
There are a total of six visits: Pre-treatment period (Day -15, Day -8 and Day -1) and
Treatment period (Day 1/ Baseline, Day 15 and Day 22).